Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25529111 | 0.82 | KDM4E (0.44) | LMNAKMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL11389408 | 0.82 | ALDH1A1 (0.45) | MAPTLMNAKMT2AALDH1A1POLB | |
| SCHEMBL25533294 | 0.78 | KDM4E (0.53) | KMT2AALDH1A1KDM4EACHE | |
| SCHEMBL29868349 | 0.77 | ALDH1A1 (0.33) | MAPTALDH1A1KDM4ESMN1; SMN2POLB | |
| SCHEMBL11636498 | 0.73 | POLB (0.42) | MAPTLMNAKMT2AALDH1A1KDM4E | |
| SCHEMBL29868162 | 0.73 | POLB (0.41) | LMNAKMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL14539772 | 0.72 | MMP1 (0.48) | MAPTLMNAKMT2AALDH1A1KDM4E | |
| SCHEMBL2540404 | 0.71 | MAPT (0.38) | MAPTKMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL20026452 | 0.71 | KDM4E (0.47) | MAPTALDH1A1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL11625877 | 0.71 | NOTUM (0.56) | MAPTLMNAKMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294804-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | Exelixis, Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| WO-2022178205-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| US-20240158393-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. | 2024-05-16 | — | — | US | disclosed |
| CN-117440951-A | Pyridone compounds and methods of use | 埃克塞里艾克西斯公司 | 2024-01-23 | — | — | CN | disclosed |
| EP-4294804-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | Exelixis, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-115605478-A | Compounds and methods of use | 埃克塞里艾克西斯公司（US） | 2023-01-13 | — | — | CN | disclosed |
| WO-2022178205-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158393-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, PLK2, MAP4K2 | MAPT 2493/4885LMNA 1686/4885KMT2A 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.